Cerda-Troncoso Cristóbal, Grünenwald Felipe, Arias-Muñoz Eloísa, Cavieres Viviana A, Caceres-Verschae Albano, Hernández Sergio, Gaete-Ramírez Belén, Álvarez-Astudillo Francisca, Acuña Rodrigo A, Ostrowski Matias, Burgos Patricia V, Varas-Godoy Manuel
Organelle Phagy Lab, CEBICEM Facultad de Medicina y Ciencia Universidad San Sebastián Santiago Chile.
Cancer Cell Biology Lab, CEBICEM, Facultad de Medicina y Ciencia Universidad San Sebastián Santiago Chile.
J Extracell Biol. 2024 May 30;3(6):e157. doi: 10.1002/jex2.157. eCollection 2024 Jun.
Chemoresistance is a common problem in ovarian cancer (OvCa) treatment, where resistant cells, in response to chemotherapy, secrete small extracellular vesicles (sEVs), known as chemo-sEVs, that transfer resistance to recipient cells. sEVs are formed as intraluminal vesicles (ILVs) within multivesicular endosomes (MVEs), whose trafficking is regulated by Ras-associated binding (RAB) GTPases that mediate sEVs secretion or lysosomal degradation. A decrease in lysosomal function can promote sEVs secretion, but the relationship between MVEs trafficking pathways and sEVs secretion in OvCa chemoresistance is unclear. Here, we show that A2780cis cisplatin (CCDP) resistant OvCa cells had an increased number of MVEs and ILVs structures, higher levels of Endosomal Sorting Complex Required for Transport (ESCRTs) machinery components, and RAB27A compared to A2780 CDDP-sensitive OvCa cells. CDDP promoted the secretion of chemo-sEVs in A2780cis cells, enriched in DNA damage response proteins. A2780cis cells exhibited poor lysosomal function with reduced levels of RAB7, essential in MVEs-Lysosomal trafficking. The silencing of RAB27A in A2780cis cells prevents the Chemo-EVs secretion, reduces its chemoresistance and restores lysosomal function and levels of RAB7, switching them into an A2780-like cellular phenotype. Enhancing lysosomal function with rapamycin reduced chemo-sEVs secretion. Our results suggest that adjusting the balance between secretory MVEs and lysosomal MVEs trafficking could be a promising strategy for overcoming CDDP chemoresistance in OvCa.
化疗耐药是卵巢癌(OvCa)治疗中的一个常见问题,其中耐药细胞在化疗作用下会分泌小细胞外囊泡(sEVs),即化疗小细胞外囊泡,它会将耐药性传递给受体细胞。sEVs作为多囊泡内体(MVE)中的腔内囊泡(ILV)形成,其运输由Ras相关结合(RAB)GTPases调节,这些GTPases介导sEVs的分泌或溶酶体降解。溶酶体功能的降低可促进sEVs的分泌,但在OvCa化疗耐药中MVE运输途径与sEVs分泌之间的关系尚不清楚。在这里,我们发现与A2780顺铂(CDDP)敏感的OvCa细胞相比,A2780顺铂耐药的OvCa细胞具有更多的MVE和ILV结构、更高水平的转运所需内体分选复合物(ESCRT)机制成分以及RAB27A。顺铂促进了A2780顺铂耐药细胞中化疗小细胞外囊泡的分泌,这些小细胞外囊泡富含DNA损伤反应蛋白。A2780顺铂耐药细胞表现出溶酶体功能较差,RAB7水平降低,而RAB7在MVE-溶酶体运输中至关重要。在A2780顺铂耐药细胞中沉默RAB27A可阻止化疗小细胞外囊泡的分泌,降低其化疗耐药性,并恢复溶酶体功能和RAB7水平,使其转变为类似A2780细胞的表型。用雷帕霉素增强溶酶体功能可减少化疗小细胞外囊泡的分泌。我们的结果表明,调整分泌性MVE和溶酶体MVE运输之间的平衡可能是克服OvCa顺铂化疗耐药的一种有前景的策略。